OGN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 6.85% compared to Organon &'s net margin of -14.12%. Organon &'s return on equity of 397.42% beat Alnylam Pharmaceuticals's return on equity of --.

Organon & has a consensus price target of $19.33, signalling upside risk potential of 81.88%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $315.57 which suggests that it could grow by 35.58%. Given that Organon & has higher upside potential than Alnylam Pharmaceuticals, analysts believe Organon & is more attractive than Alnylam Pharmaceuticals.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.54%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Organon &'s net income of $109M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Organon &'s price-to-earnings ratio is 3.19x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.43x versus 13.21x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Biogen has a net margin of 6.85% compared to Organon &'s net margin of 10.87%. Organon &'s return on equity of 397.42% beat Biogen's return on equity of 10.33%.

Organon & has a consensus price target of $19.33, signalling upside risk potential of 81.88%. On the other hand Biogen has an analysts' consensus of $191.53 which suggests that it could grow by 64.42%. Given that Organon & has higher upside potential than Biogen, analysts believe Organon & is more attractive than Biogen.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.54%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are smaller than Biogen quarterly revenues of $2.5B. Organon &'s net income of $109M is lower than Biogen's net income of $266.7M. Notably, Organon &'s price-to-earnings ratio is 3.19x while Biogen's PE ratio is 10.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.43x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 6.85% compared to Organon &'s net margin of --. Organon &'s return on equity of 397.42% beat Palatin Technologies's return on equity of --.

Organon & has a consensus price target of $19.33, signalling upside risk potential of 81.88%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 2930.3%. Given that Palatin Technologies has higher upside potential than Organon &, analysts believe Palatin Technologies is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.54%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Palatin Technologies quarterly revenues of --. Organon &'s net income of $109M is higher than Palatin Technologies's net income of --. Notably, Organon &'s price-to-earnings ratio is 3.19x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.43x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.85% compared to Organon &'s net margin of 31.35%. Organon &'s return on equity of 397.42% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Organon & has a consensus price target of $19.33, signalling upside risk potential of 81.88%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 4.38%. Given that Organon & has higher upside potential than Vertex Pharmaceuticals, analysts believe Organon & is more attractive than Vertex Pharmaceuticals.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 10.54%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 34.38% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Organon &'s net income of $109M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Organon &'s price-to-earnings ratio is 3.19x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.43x versus 11.24x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.